Sweden, United States
Flow Neuroscience, founded in 2016, is reimagining the treatment paradigm for Major Depressive Disorder with innovative solutions that prioritize patient-led care. With its headquarters in the United States, the company stands at the forefront of mental health technology through its unique integration of neuromodulation techniques.
Flow Neuroscience distinguishes itself as the creator of the first and only FDA-approved at-home, first-line tDCS treatment for depression. This development underscores their commitment to deliver mental healthcare that aligns with patients' lifestyles, offering an evidence-backed, clinically effective, and convenient therapy option.
Supported by robust data, including a pivotal RCT published in Nature Medicine and extensive Real-World Evidence (RWE) from over 60,000 patients, Flow Neuroscience is advancing mental health solutions. The company received its latest investment through the Support Program from MedTech Innovator in June 2023, positioning itself for continued growth and innovation in clinical-grade brain stimulation globally.
